bioRxiv Science⌕ Search

Biology subjects

Herraez-Aguilar, D.

Publications and source records attributed to Herraez-Aguilar, D..

2 recordsLinked to original sources

Metabolic Rigidity as a Mechanical Barrier to Malaria: Flickering Loss in PKLR-Deficient Erythrocytes

Pyruvate kinase (PK) deficiency is a rare hereditary enzymopathy caused by mutations in the PKLR gene, leading to reduced glycolytic ATP production in red blood cells (RBCs) and contributing to chronic hemolytic anemia. Here, we use high-speed flickering spectroscopy and passive microrheology to assess how ATP depletion reshapes the nanomechanical properties of RBC membranes. Compared to healthy controls, PKLR-mutant erythrocytes exhibit marked reductions in ATP-dependent flickering amplitude and membrane fluidity, consistent with impaired metabolic elasticity. Strikingly, when infected with Plasmodium yoelii, these metabolically rigidified cells retain mechanical properties that appear to hinder parasite-induced membrane remodeling. By mapping single-cell viscoelastic landscapes across healthy, mutated, infected and coinfected mouse RBC populations, we uncover a potential biomechanical barrier against malaria imposed by glycolytic insufficiency. These findings highlight a mechanobiological axis of host resistance and position label-free flickering analysis as a powerful tool for diagnosing RBC enzymopathies and probing infection susceptibility at the single-cell level.

biophysics↗

ELOVL6 as a Therapeutic Target: Disrupting c-MYC-Driven Lipid Metabolism to Enhance Chemotherapy in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease, marked by a survival rate of only 12%. Consequently, the exploration of novel therapeutic strategies becomes a critical clinical imperative. Among the genetic alterations contributing to PDAC, c-MYC overexpression arises due to upstream mutations, amplifications, and copy number alterations. c-MYC serves as a key regulator in the tumors metabolic reprogramming, playing a pivotal role in proliferation, migration, and metastasis. This study delves into the investigation of the role of the elongase ELOVL6 in c-MYC-induced cell transformation and its potential as a therapeutic target in PDAC. Here, we demonstrate that c-MYC regulates lipid elongation to promote cell transformation, offering a new avenue for therapeutic intervention. Initially, we show the direct regulation of ELOVLs expression by c-MYC in various PDAC mouse models and cell lines, elucidating its upregulation during transformation and tumor progression. Genetic or chemical inhibition of ELOVL6 results in decreased proliferation and migration, accompanied by alterations in fatty acid elongation. These changes in fatty acid composition led to modifications in membrane rigidity, permeability, and thickness, which collectively affect micropinocytosis and macropinocytosis. Importantly, we observe an increase in Abraxane uptake and a synergistic effect when combined with ELOVL6 interference in vitro. In vivo validation demonstrates that ELOVL6 inhibition significantly reduces tumor growth and enhances the response to Abraxane, thereby increasing overall survival. Altogether, these results position ELOVL6 as a promising therapeutic target in the treatment of PDAC.

cancer biology↗